Bioxyne
(ASX:BXN)

News

Market Highlights: Wall Street halts winning streak, but Netflix and gold price hit record highs

August 21, 2024August 21, 2024 | Eddy Sunarto

Investor Guides

Investor Guide: Health & Biotech FY2025 featuring Tim Boreham

August 7, 2024October 11, 2024 | Nadine McGrath and Tim Boreham

News

Rise and Shine: Everything you need to know before the ASX opens

July 31, 2024July 31, 2024 | Gregor Stronach

News

CLOSING BELL: ASX down 0.5pc, FMG down 10.2pc, and it looks like Rex is down for the count

July 30, 2024July 30, 2024 | Gregor Stronach

Health & Biotech

ASX wellness stocks offering calm and anxiety relief – Part 1

June 20, 2024June 20, 2024 | Nadine McGrath

Health & Biotech

Bioxyne highlights risks of unregulated psychedelic use

May 28, 2024May 28, 2024 | Special Report

Health & Biotech

So mushroom for growth: Bioxyne subsidiary inks psilocybin deal with Swiss pharma company

May 14, 2024May 14, 2024 | Special Report

News

Closing Bell: Oil weighs on flat ASX; Errawarra jumps 65pc on scent of fresh lithium

May 13, 2024October 1, 2024 | Eddy Sunarto

Health & Biotech

ASX Quarterly Health Wrap: Which companies are making progress in clinical trials?

May 2, 2024May 2, 2024 | Nadine McGrath

Health & Biotech

Bioxyne subsidiary granted upgraded wholesale licence for MDMA and psilocybin finished products

April 16, 2024 | Special Report

Health & Biotech

‘Monumental’– Bioxyne subsidiary awarded Australia’s first GMP licence to manufacture psilocybin and MDMA

February 7, 2024June 28, 2024 | Special Report

News

Rise and Shine: Everything you need to know before the ASX opens

February 6, 2024February 6, 2024 | Gregor Stronach

News

Closing Bell: Aussie stocks dive as big miners dig a great hole through Monday

February 5, 2024February 5, 2024 | Christian Edwards and Gregor Stronach

News

ASX Small Caps Lunch Wrap: Who was running really, really late to work today?

February 5, 2024February 5, 2024 | Gregor Stronach

News

Top 10 at 10: Legal mushrooms? The party is at Bioxyne’s house

February 5, 2024February 5, 2024 | Reuben Adams

News

In Case You Missed It: Key approvals for resource plays and Aroa looks to improve mastectomy surgery

January 29, 2024January 15, 2025 | Nadine McGrath

Health & Biotech

Bioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growth

January 29, 2024January 29, 2024 | Special Report

Health & Biotech

Bioxyne subsidiary unveils platform for transparent pricing in Australia’s B2B medical cannabis market

January 22, 2024January 22, 2024 | Special Report